Back to Stakeholders
Research, Drug Development & ManufacturingLead program: Pre-clinical

Kuleon Bioscience

1 Drug Candidate

Kuleon Bioscience is a Seattle-based drug discovery company leveraging AI-based technology to identify novel serotonergic drugs for neuropsychiatric diseases. The company specialises in biased serotonin receptor ligands — including the world's first known trifunctional 5-HT2C agonist / 5-HT2A antagonist / 5-HT2B antagonist — designed to deliver therapeutic efficacy without hallucinogenic or cardiotoxic side effects. Its lead programme KB-128 targets alcohol use disorder and is supported by a $2 million NIAAA grant.

Drug Pipeline

1

KB-128

Pre-clinical
Alcohol Use Disorder (AUD)

First-in-class trifunctional 5-HT2C agonist / 5-HT2A antagonist / 5-HT2B antagonist with biased G-protein signaling. $2M NIAAA grant awarded September 2025 to advance AUD programme.

Quick Facts

Type
Private Biotech
Founded
2021
Lead Stage
Pre-clinical
Website
Visit